Rapid Micro Biosystems, Inc.
RPID · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.07 | 0.04 | 0.03 | -0.10 |
| FCF Yield | -116.06% | -147.39% | -136.09% | -13.19% |
| EV / EBITDA | -0.61 | -0.28 | -0.48 | -5.75 |
| Quality | ||||
| ROIC | -61.04% | -44.66% | -36.17% | -21.21% |
| Gross Margin | -0.39% | -24.36% | -49.85% | -33.32% |
| Cash Conversion Ratio | 0.94 | 0.86 | 0.96 | 0.75 |
| Growth | ||||
| Revenue 3-Year CAGR | 17.86% | -1.03% | 2.14% | 12.05% |
| Free Cash Flow Growth | 3.00% | 28.12% | -12.21% | -83.62% |
| Safety | ||||
| Net Debt / EBITDA | 0.23 | 0.32 | 0.32 | 3.89 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | -17.82 |
| Efficiency | ||||
| Inventory Turnover | 1.39 | 1.40 | 1.21 | 1.98 |
| Cash Conversion Cycle | 326.88 | 324.95 | 340.82 | 226.68 |